Abstract
In order to investigate the mechanism of amelioration of metabolic abnormalities with supplementary doses of insulin, islet B‐cell function and insulin sensitivity were measured in 10 patients with Type 2 diabetes in secondary failure to oral agents. A small dose of ultralente insulin (0.26 ± 0.07 U kg‐ideal‐body‐weight−1) was added in the morning before breakfast. After 3 months insulin therapy and progressive improvement of metabolic control (HbA1 from 10.5 ± 0.4 to 9.0 ± 0.3 % at the end of insulin treatment, p < 0.001), basal C‐peptide and incremental area during an oral glucose tolerance test were unchanged. In vivo peripheral insulin sensitivity (euglycaemic clamp with insulin infusion of 40, 160, and 600 mU m−2 min−1, respectively) was significantly improved (glucose requirement: to 4.7 ± 1.0 from 3.0 ± 0.6 mg kg−1 min−1, p< 0.05 at first insulin level; to 10.8 ± 0.5 from 9.3 ± 0.7 mg kg−1 min−1, p<0.01 at second level; to 13.3 ± 0.6 from 11.8 ± 0.8 mg kg−1 min−1, p< 0.025 at third level). Basal hepatic glucose production was also significantly reduced (from 4.3 ± 0.4 to 3.3 ± 0.3 mg kg−1 min−1, p< 0.05), and residual glucose production further suppressed after insulin supplement (from 1.1 ± 0.4 to 0.3 ± 0.2 mg kg−1 min−1 after 120 min at 100 mU I−1 plasma insulin, p< 0.05). Specific insulin binding to mononuclear leucocytes was unchanged (from 3.1 ± 0.3 to 3.5 ± 0.3 %, NS). 1990 Diabetes UK
Lingua originale | Inglese |
---|---|
pagine (da-a) | 805-809 |
Numero di pagine | 5 |
Rivista | Diabetic Medicine |
Volume | 7 |
Numero di pubblicazione | 9 |
DOI | |
Stato di pubblicazione | Pubblicato - nov 1990 |
Pubblicato esternamente | Sì |